--- title: "CR Sanjiu will distribute over 1.7 billion in cash in 2025, highlighting a high dividend payout that underscores its dividend characteristics" type: "News" locale: "en" url: "https://longbridge.com/en/news/287993566.md" description: "CR Sanjiu will distribute a cash dividend of approximately 1.731 billion yuan to shareholders in the fiscal year 2025, accounting for 50.59% of the annual net profit attributable to the parent company. This dividend marks the company's second cash dividend, reflecting its high and sustainable dividend policy. Since its listing, the company has implemented cash dividends 24 times, totaling over 10 billion yuan, becoming a benchmark for dividends in the A-share pharmaceutical sector" datetime: "2026-05-29T01:37:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287993566.md) - [en](https://longbridge.com/en/news/287993566.md) - [zh-HK](https://longbridge.com/zh-HK/news/287993566.md) generator: "portal-rs" --- # CR Sanjiu will distribute over 1.7 billion in cash in 2025, highlighting a high dividend payout that underscores its dividend characteristics A sustained high proportion of cash dividends is becoming an important way for listed companies to reward shareholders and fulfill corporate social responsibility. On May 29, CR Sanjiu's cash dividends for the year 2025 were credited. According to the company's announcement on the implementation of equity distribution, this dividend distributes a cash dividend of 5.90 yuan (including tax) for every 10 shares to all shareholders, totaling approximately 982 million yuan in cash dividends. This is the second cash dividend CR Sanjiu has issued in the year 2025. Combined with the previously implemented semi-annual dividend, investors will receive a total cash dividend of approximately 1.731 billion yuan for the entire year of 2025. In terms of both the size of the dividend and the frequency of distribution, it ranks among the top tier in the entire pharmaceutical listed sector. As a leading pharmaceutical company with annual revenue exceeding 10 billion yuan, CR Sanjiu has long placed investor returns in a prominent position, adhering to a sustainable and stable dividend policy to share development results with investors, effectively rewarding shareholders' trust, and demonstrating the responsibility and commitment of state-owned listed companies. **Dividend efforts continue to increase, cumulative returns exceed 10 billion yuan** In the year 2025, CR Sanjiu has cumulatively distributed approximately 1.731 billion yuan to shareholders, accounting for 50.59% of the company's annual net profit attributable to the parent company. This means that CR Sanjiu will convert more than half of its net profit into real cash returns for investors in 2025, actively sharing operational results with shareholders through actions and practicing the company's "high proportion, sustainable" dividend policy. Such a high dividend ratio is not coincidental. Since its listing, CR Sanjiu has cumulatively implemented cash dividends 24 times, sharing a total cash dividend of over 10 billion yuan with investors. If calculated based on the net amount of approximately 1.666 billion yuan raised at the time of the company's initial public offering, its cumulative dividend scale has reached more than six times the raised funds. Over the past three years, the company's cash dividend ratio has further increased, with the dividend payout ratio exceeding 50% from 2023 to 2025. The continuous and stable dividend record has made CR Sanjiu a true benchmark for dividends in the A-share pharmaceutical sector. Not only is the total amount of dividends considerable, but CR Sanjiu's dividend rhythm has also been continuously optimized in recent years. As a state-controlled listed company, the company actively responds to the State Council's "Several Opinions on Strengthening Supervision, Preventing Risks, and Promoting High-Quality Development of the Capital Market," implementing the work requirements to "enhance the stability, sustainability, and predictability of dividends, promote multiple dividends within a year, pre-dividends, and dividends before the Spring Festival," effectively enhancing investors' sense of gain. In 2024, CR Sanjiu implemented a third-quarter dividend for the first time, distributing 10 yuan in cash for every 10 shares, initiating a model of multiple dividends within the year. In 2025, the company achieved two distributions of cash dividends through semi-annual and annual dividends, demonstrating the central enterprise's responsibility to effectively safeguard investors' interests with concentrated and stable cash returns. **Steady Growth Across Cycles, Confidence Behind High Dividends** The high proportion and frequency of dividends are the result of the company's years of steady operations. Currently, China's pharmaceutical industry is undergoing a deep adjustment period. With the normalization of centralized procurement and the comprehensive rollout of medical insurance payment reform, the overall profit margins in the industry are under continuous pressure; coupled with fluctuations in the prices of raw materials such as traditional Chinese medicine, companies face challenges in controlling operating costs. Global medical consulting firm IQVIA predicts that from 2023 to 2028, the compound annual growth rate of China's pharmaceutical market will be only 2.6%, with the industry entering a low growth phase. Against this backdrop, CR Sanjiu has maintained a steady growth trend. Since its listing in 2000, the company's revenue has achieved a cumulative growth of 15 times, increasing from less than 2 billion yuan to 31.603 billion yuan by 2025, with an average annual compound growth rate of 12.08%. During the "14th Five-Year Plan" period, the growth rate further accelerated, with the company's revenue and net profit doubling within five years; the increase in operating cash flow reached 147.89%, with a five-year compound growth rate approaching 20%, which is quite remarkable in the industry. With performance characterized by "stability," CR Sanjiu's confidence comes from the core moat built by brand and channel advantages. In the CHC (self-medication) health consumer goods sector, the company centers around the "999" national brand, boasting several well-known star products such as 999 Cold Medicine, 999 Dermatitis Cream, and Sanjiu Weitai, while gradually developing well-known brands in niche areas like "Tianhe," "Shunfeng," and "Aonuo," forming a solid "1+N" brand matrix. On the channel side, the company has built a mature sales network covering both online and offline, with over 600,000 cooperative pharmacies by 2025, efficiently promoting brand products to consumers' doorsteps. This deep combination of brand recognition and channel coverage has established the foundation for CR Sanjiu's steady growth. By 2025, the company's CHC segment is expected to achieve revenue of 15.111 billion yuan. Public information shows that the sales of Cold Medicine Granules have ranked first in retail pharmacy sales of respiratory traditional Chinese medicine for several years; the sales of Compound Cold Medicine Granules, Antiviral Oral Liquid, and Xiao Chai Hu Granules are also expected to achieve double-digit growth in 2025, with CR Sanjiu's market share in the respiratory category expanding to over 10%, becoming the preferred brand for consumers purchasing medicine. As the A-share annual report season comes to a close, the market's demand for high-certainty dividend assets continues to rise. In this context, brokerages have given CR Sanjiu a "Buy" rating, believing that its fundamentals are solid and its risk resistance is outstanding. With a clear strategic layout, stable operational characteristics, and the ability to generate profits across cycles, CR Sanjiu is expected to continue stable dividends in the future, rewarding shareholders with real returns, solidifying its position as a benchmark for state-owned enterprises, and fulfilling its responsibility and commitment to return to investors ### Related Stocks - [000999.CN](https://longbridge.com/en/quote/000999.CN.md) - [IQV.US](https://longbridge.com/en/quote/IQV.US.md) ## Related News & Research - [20:17 ETBingX Launches "Connect What's Moving" to Bring Users Closer to Global Market Opportunities](https://longbridge.com/en/news/297711060.md) - [17:00 ETMidea SMART MASTER at IFA 2026: From AI Agents to Embodied Intelligence](https://longbridge.com/en/news/298075831.md) - [10:17 ETDarkforce™ advances toward FedRAMP High for government deployment](https://longbridge.com/en/news/297666526.md) - [17:00 ETSpencer Spirit Holdings, Inc. Completes Acquisition of Hot Topic, Inc.](https://longbridge.com/en/news/297830707.md) - [12:17 ETDSC® Unveils MORPH Adaptable Materials Platform and Advanced Foam Construction](https://longbridge.com/en/news/297811010.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**